165 related articles for article (PubMed ID: 8428693)
1. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype.
Safrit JT; Berek JS; Bonavida B
Gynecol Oncol; 1993 Feb; 48(2):214-20. PubMed ID: 8428693
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance.
Safrit JT; Bonavida B
Cancer Res; 1992 Dec; 52(23):6630-7. PubMed ID: 1330298
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines.
Morimoto H; Safrit JT; Bonavida B
J Immunol; 1991 Oct; 147(8):2609-16. PubMed ID: 1918981
[TBL] [Abstract][Full Text] [Related]
4. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha.
Licht T; Lübbert M; Martens C; Bross KJ; Fiebig HH; Mertelsmann R; Herrmann F
Cytokines Mol Ther; 1995 Jun; 1(2):123-32. PubMed ID: 9384669
[TBL] [Abstract][Full Text] [Related]
5. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins.
Morimoto H; Yonehara S; Bonavida B
Cancer Res; 1993 Jun; 53(11):2591-6. PubMed ID: 7684321
[TBL] [Abstract][Full Text] [Related]
6. The relationship between multidrug resistance and tumor necrosis factor resistance in an EL4 cell line model.
Ujhazy P; Chen YF; Fredericks W; Ho RL; Mihich E; Baker RM; Ehrke MJ
Cancer Commun; 1990; 2(5):181-8. PubMed ID: 1973358
[TBL] [Abstract][Full Text] [Related]
7. Combined activity of interleukin-1 alpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects.
Borsellino N; Crescimanno M; Flandina C; Flugy A; D'Alessandro N
Anticancer Res; 1994; 14(6B):2643-8. PubMed ID: 7872695
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
9. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
[TBL] [Abstract][Full Text] [Related]
10. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
11. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
12. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
Wu L; Smythe AM; Stinson SF; Mullendore LA; Monks A; Scudiero DA; Paull KD; Koutsoukos AD; Rubinstein LV; Boyd MR
Cancer Res; 1992 Jun; 52(11):3029-34. PubMed ID: 1350507
[TBL] [Abstract][Full Text] [Related]
14. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
Mizutani Y; Yoshida O; Miki T; Bonavida B
Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639
[TBL] [Abstract][Full Text] [Related]
15. [Synergistic effect of bromocriptine combining tumor necrosis factor-alpha on reversing multidrug resistance in a nude mouse model of liver neoplasm].
Ding L; Chen XP; Zhang ZW; Wang H; Cao B; Wang ZH; Li CL
Zhonghua Wai Ke Za Zhi; 2005 Oct; 43(19):1248-53. PubMed ID: 16271222
[TBL] [Abstract][Full Text] [Related]
16. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance.
Minderman H; Vanhoefer U; Toth K; Minderman MD; Rustum YM
Cancer; 1996 Dec; 78(11):2427-36. PubMed ID: 8941015
[TBL] [Abstract][Full Text] [Related]
17. The effect of the plasticizer diethylhexyl phthalate on transport activity and expression of P-glycoprotein in parental and doxo-resistant human sarcoma cell lines.
Angelini A; Centurione L; Sancilio S; Castellani ML; Conti P; Di Ilio C; Porreca E; Cuccurullo F; Di Pietro R
J Biol Regul Homeost Agents; 2011; 25(2):203-11. PubMed ID: 21880209
[TBL] [Abstract][Full Text] [Related]
18. In vitro growth inhibition of cisplatin-resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon-gamma by virtue of collateral sensitivity.
Hong WS; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Takahashi H; Nakano H; Nakagawa K; Twentyman PR
Jpn J Cancer Res; 1987 Nov; 78(11):1274-80. PubMed ID: 3121562
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum.
Uslu R; Bonavida B
Cancer; 1996 Feb; 77(4):725-32. PubMed ID: 8616765
[TBL] [Abstract][Full Text] [Related]
20. Alpha-tocopheryl succinate enhances doxorubicin-induced apoptosis in human gastric cancer cells via promotion of doxorubicin influx and suppression of doxorubicin efflux.
Zhang X; Peng X; Yu W; Hou S; Zhao Y; Zhang Z; Huang X; Wu K
Cancer Lett; 2011 Aug; 307(2):174-81. PubMed ID: 21536373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
